Q-omics provides the consensus-scored TRIM64FP profile across patient tissues and cancer cell-line models. TRIM64FP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRIM64FP is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, TRIM64FP RNA expression shows 11,600 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BLCA, and UVM as cancer lineages where TRIM64FP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM64FP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM64FP survival associations across molecular data types. TRIM64FP RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM64FP RNA expression–survival associations across cancer types. High TRIM64FP expression shows unfavorable associations in UVM, KIRP, HNSC, READ and KICH, but favorable associations in ACC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for TRIM64FP RNA expression.
This table summarizes TRIM64FP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM64FP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM64FP shows lower tumor expression in KIRC, KICH, THCA, LUSC and LUAD and higher tumor expression in BLCA. The BLCA box plot shows higher TRIM64FP RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p = .004).
This table shows molecular features associated with TRIM64FP in patient tissues and cancer cell lines. In patient samples, TRIM64FP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
